HHS 'expects to renew' COVID-19 emergency, spokesperson says

The department did not respond to requests for comment Tuesday morning. The public health emergency is currently set to expire at the end of July.

By Shannon Muchmore • June 30, 2020

As Beckman enters US COVID-19 antibody market, how do rivals compare?

Comparing the accuracy of the Danaher subsidiary's test to products from big rivals like Abbott, Roche and Siemens Healthineers depends on who's doing the assessment and when a sample is taken.

By Nick Paul Taylor • June 30, 2020

Explore the Trendline➔

Medical device industry continues to turn to AI

While the industry continues to embrace artificial intelligence, there are still questions about how the new technologies need to be regulated and if they are effective.

By MedTech Dive staff

FDA nod to Boston Scientific cardiac monitor clears challenge to Abbott, Medtronic

The medtech giant is betting remote adjustment will put its LUX-Dx insertable system in a position to take on rivals, which have a years-long head start.

By Nick Paul Taylor • June 29, 2020

Labs warn COVID-19 testing demand will soon top capacity as new hotspots emerge

With the spike in coronavirus cases in the South and West, commercial labs say they don't have the resources to keep up. Quest said in an update late Monday turnaround times for some molecular test results are now 3 to 5 days.

By Greg Slabodkin • Updated June 30, 2020

Payer coverage of employer, surveillance COVID-19 tests not required, feds say

As return-to-work offerings proliferate from lab and pharmacy giants like Quest, LabCorp and CVS, new federal guidance says health insurers aren't obligated to pay for the testing services.

By Maria Rachal • June 25, 2020

UK study to validate, compare COVID-19 tests in real-world settings

The hospital arm will assess 10 to 20 new diagnostics the National Health Service has identified as high priority, including those designed to deliver results at the point of care in minutes, which could include Abbott’s ID NOW.

By Nick Paul Taylor • June 25, 2020

Fauci: Trump never asked to slow down testing, says US needs more, not less

During a House panel Tuesday, top U.S. infectious disease doctor Anthony Fauci and other public health officials denied they'd been directed to impede testing efforts as the White House targets up to 50 million tests a month by fall.

By Rebecca Pifer • June 24, 2020

5-minute, quantitative COVID-19 antibody test snags BARDA backing

MBio's offering could assess whether a patient has protective levels of antibodies and is a candidate to donate convalescent plasma, a potential treatment for critically ill COVID-19 patients.

By Susan Kelly • June 24, 2020

CVS launches COVID-19 return-to-work service with testing

Questions about testing accuracy and hesitancy by employers haven't stopped big healthcare companies, including Quest, LabCorp and UnitedHealth Group, from jumping into the space with new products.

By Rebecca Pifer • June 24, 2020

New Guardant genomic database could be worth $2B, analysts say

The company said clinical information from repeat liquid biopsies in its 86,000-patient database will show how tumors evolve, information that may be attractive to biopharma partners.

By Nick Paul Taylor • June 24, 2020

No silver bullet: LabCorp and Quest hawk return-to-work COVID-19 tests but employers not rushing in

One employer group official noted "hype" around antibody testing with inconclusive evidence about the immunity of individuals who test positive for the antibodies. 

By Greg Slabodkin • June 22, 2020

BARDA backs study of Empatica's COVID-19 early warning platform

The system, which measures physiological data including blood volume pulse and electrodermal activity, is the latest in a growing list of wearables being primed to detect and monitor infections.

By Susan Kelly • June 22, 2020

Trump admin sitting on $14B for testing, tracing, Democratic senators say

A letter urging the administration to ramp up its COVID-19 spending comes a day after President Donald Trump told a rally he had directed officials to slow down testing to keep case numbers low.

By Rebecca Pifer • June 22, 2020

Invitae cash-and-stock buyout of ArcherDX a done deal

The medical genetic testing company swept in after the assay developer announced plans to go public. Invitae will now offer tests for more stages of cancer care, from assessing disease risk to monitoring its progression.

By Maria Rachal • Updated Oct. 5, 2020

Pandemic pushes FDA to 'accelerate' real-world evidence efforts, Hahn says

The agency has grappled with how to leverage real-world data in regulating medical devices, and is now leaning on it to update emergency use authorizations, FDA chief Stephen Hahn said at a forum on Thursday.

By Maria Rachal • June 19, 2020

FDA cracks down on sellers of at-home COVID-19 antibody tests

A series of warning letters is the latest example of U.S. regulators weeding out serology tests that don't meet the agency's standards.

By Nick Paul Taylor • June 18, 2020

TÜV SÜD becomes 4th notified body designated under IVDR

It's the first notified body OK'd by the European Commission in 2020 to increase capacity for the forthcoming In Vitro Diagnostic Regulation, set to come into force in less than two years.

By Nick Paul Taylor • June 18, 2020

FDA revokes emergency authorization for Chembio's COVID-19 antibody test

It's the first time the agency has exercised such authority for a coronavirus test, citing more false results than expected. Chembio Diagnostics' stock plunged 60% Wednesday.

By Greg Slabodkin • June 17, 2020

NIH loops Quest into effort to test 10K Americans for antibodies against coronavirus

The agency did not disclose which antibody test it will use as part of the All of Us initiative, saying only that the assay has FDA emergency use authorization and is designed to detect IgG antibodies. 

By Nick Paul Taylor • June 17, 2020

Myriad prostate cancer test wins coverage from Aetna

The decisions by the insurance giant and two others nearly double commercial coverage for the Prolaris test, days after a local Medicare contractor found there may be insufficient data to back Myriad's GeneSight combinatorial tests.

By Susan Kelly • June 16, 2020

Labs urge CDC to change COVID-19 antibody test guidelines

The trade group for Quest Diagnostics and LabCorp criticized the federal agency's advice against use of serology test results to make decisions about who can return to work.

By Nick Paul Taylor • June 16, 2020

COVID-19 diagnostic testing costs may hit $25B per year, AHIP study finds

And on the antibody testing front, costs could range between $5.2 billion and $19.1 billion, according to a report commissioned by the payer trade group.

By Shannon Muchmore • June 11, 2020

Cue Health raises $100M to scale up rapid, portable coronavirus test

The startup, which counts J&J among its backers, said on Friday it received FDA emergency use authorization for its test, allowing use anywhere under the supervision of qualified medical personnel. 

By Nick Paul Taylor • Updated June 12, 2020

MedTech Europe pitches virtual audits to clear MDR coronavirus logjam

The trade group contends technology such as smart glasses and webcams can enable notified bodies to view facilities without having to visit in person.

By Nick Paul Taylor • June 11, 2020

Cepheid developing test to distinguish COVID-19 from flu

The company, which plans to pursue the FDA's emergency use authorization pathway for the four-in-one combination test, is aiming to have it ready for next flu season, when a potential spike in coronavirus cases could occur.

By Susan Kelly • June 10, 2020